5 mg semaglutide dose Dosing Medical Weight Loss Education Materials

Learn More Semaglutide Single-receptor (GLP-1) FDA-approved branded peer

however, randomized controlled trials and a large international cohort study have shown no increases in thyroid cancer risk in humans.[7779] Isolated study findings have also raised concerns about ocular adverse events, including retinopathy and non-arthritic anterior ischemic optic neuropathy (NAION).[11, 80] However, to date, meta-analyses have failed to find associations between GLP-1RAs and NAION, and only albiglutide, a GLP-1RA discontinued in 2017, has been associated with an increased risk of retinopathy.[80, 81] In adults 66 years and older with diabetes, a cohort study found a two-fold increase in risk for neovascular age-related macular degeneration in those using GLP-1RAs for one year or more.[82] Accessibility Despite the expanding indications and potential therapeutic benefits of GLP-1RAs, disparities in cost-related access may hinder their utilization in populations that stand to benefit the most.[83] In the U.S., individuals identifying as Hispanic and non-Hispanic Blackgroups with higher obesity prevalencedemonstrate significantly lower initiation rates of GLP-1RAs compared to individuals identifying as White.[83, 84] Additionally, individuals enrolled in Medicaid, Medicare, or lacking insurance are less likely to initiate GLP-1RA therapy relative to those with private insurance coverage

As your body adjusts to the medication, you may also experience improved blood sugar control, which can further enhance your weight loss results and overall health

Mansi C, Savarino V, Vigneri S, et al

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed to treat type 2 diabetes, but clinical research has shown it produces significant weight loss in people with obesity

You may be able to reach your goals at lower doses, depending on how your body responds and your diet and exercise habits